Enabled by WuXi Biologics’ industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injection, as the first and the only locally developed enzyme replacement therapy (ERT) for Gaucher disease in China, marks a significant breakthrough for CANbridge Pharmaceuticals and WuXi Biologics in advancing R&D...
Latest News
UPTON, NY – Researchers at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory have demonstrated a new, highly detailed x-ray imaging technique that could be developed into a method for early diagnosis of Alzheimer’s disease. The technique has previously been used to look at tumors in breast tissue and...
BOSTON, Mass. — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food and Drug Administration (FDA) has approved XOLREMDI™ (mavorixafor) capsules for use in patients 12 years of age and older with WHIM...
X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced that, effective on February 28, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”).
Chicago, Illinois – Xentria, a clinical-stage biopharmaceutical company advancing therapies for rare and serious diseases, today announced the successful completion of enrollment in the therapeutic dose-ranging phase of its global XTMAB16 Study in pulmonary sarcoidosis, an immune-mediated inflammatory disorder with few available treatment options. The dose-ranging study successfully enrolled 39...
CHICAGO – Xentria Inc., a biopharmaceutical company focused on developing novel biologics to address unmet clinical needs, today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed that the Company satisfactorily addressed all requirements and can proceed with initiation of the planned Phase 1 clinical trial of XTMAB-16....
CHICAGO – Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ: SBBP) (“Strongbridge”) by Xeris. At the special meeting of Xeris stockholders held on September 14, 2021, approximately 97% of the shares voted were...
XNK Therapeutics will perform a proof of concept study in acute myeloid leukemia (AML) using patient samples from The University of Texas MD Anderson Cancer Center. The proof of concept study is to determine the feasibility to expand and activate NK cells from patients with AML using XNK’s platform. The...
STOCKHOLM – XNK Therapeutics AB (“XNK”) today announced that it is entering into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s leading drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa (isatuximab). XNK and Sanofi are both collaborative partners within NextGenNK Competence Center coordinated...
CALGARY, Alberta — XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a research paper titled “Raising serum uric acid with a uricase inhibitor worsens PKD in...